Across TCGA pan-cancer cohorts, ZBTB12 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZBTB12 data layer compared with 28 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher ZBTB12 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZBTB12 expression acts as an unfavorable survival marker, although some lineages such as BLCA and SCLC show a favorable association.

SARC, BLCA, and SKCM are the cancer types where ZBTB12 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	OS	Median	All	0.175	0.745	.007	6	view →
BLCA	DFS	Median	All	1.000	0.329	.035	6	view →
SKCM	OS	Median	IV	0.415	0.861	.014	6	view →
SCLC	OS	Median	III,IV	1.000	0.413	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: ZBTB12 tumor-vs-normal RNA expression · all ZBTB12 data types